Offense and Defense in One iPSC Platform...
with YOU in mind.
iPSC: Offense & Defense in One Platform
User-friendly iPSC reprogramming kits and starting iPSC cell lines that deliver a safe, footprint free starting point for your differentiation needs.
Our proprietary method uses non-integrating, episomal DNA and small molecule inhibitors that reprogram starting cell colonies safely and efficiently. Unlike other reprogramming techniques, which require multiple transfections and 3-4 weeks to clear delivery vectors, our technology requires a single transfection step and delivers reprogrammed colonies in under 20 days with no karyotypic abnormalities. Our portfolio of normal and disease model iPSCs have been reprogrammed in the absence of proto-oncogenes MYC and Lin28, minimizing downstream oncogenic risks for therapeutic developers.
Reprogramming How You Reprogram Cells
A patented method that is primary cell agnostic, virus free and simple to replicate in-house.
Our method can be used with primary fibroblast or peripheral blood mononuclear cells (PBMCs) such as lymphocytes, monocytes, and dendritic cells. Starting cells can be adapted for adherent growth or suspension-based applications, and our protocols can be adapted for traditional electroporation or chemically mediated transfection, depending on your preferred method. Let our flexible reprogramming technologies bring your iPSC generation steps in-house, saving valuable weeks and months versus an outsourced alternative.
iPSC Technology Developed with YOU in mind.
Single versus Multiple Transfection Steps
Many existing reprogramming methods, such as synthetic RNA, require many transfections over and weeks to ensure successful delivery of exogenous reprogramming factors. Our iPSC Complete Reprogramming Kit has shown transduction efficiency after a single transfection step, saving you precious hands-on time and valuable reagent consumption. Let our iPSC efficiency developments empower your research efforts.
Non-integrative vs. Integrative Systems
Episomal vectors provide an efficient alternative to integrative viral and non-viral delivery systems, and before, and present significantly lower risk for insertional mutagenesis and innate immune response. Due to their transient nature, episomal DNA is lost from cells at a rate of 5% per cell generation, hence episomal-free iPSC can typically be harvested by day 14 from initial transfection.
Avoidance of MYC
The MYC family of proto-oncogenes are used in many iPSC reprogramming vectors to boost cell reprogramming efficiency, but are among the most commonly activated oncoproteins in cancer1. Additionally, some reprogramming methods such as Sendai virus and RNA-based approaches have been shown to overexpress exogenous MYC, which increases oncogenic risks and potentially altering ratios of other reprogramming factors2. Attempts to replace MYC transcription factors, have come at the cost of lower programming efficiencies. At CET, our proprietary method replaces MYC with small molecule inhibitors without compromising efficiency.
1Dhanasekaran, R. et al. The MYC oncogene-the grand orchestrator of cancer growth and immune evasion. Nature Reviews Clinical Oncology 19, 23-36 (2022).
2 D Los Angeles, A, Hug CB, Gladyshev VN, Church GM et al. Sendia virus persistence questions the transient naive reprogramming method for iPSC generation. bioRxiv 12 (2024).
Easy to Replicate Workflow
Reprogramming Kit & Protocols designed with YOU in mind.
A comprehensive kit containing core reprogramming and cell growth/culturing media and supplements designed to increase the efficiency of iPS cell reprogramming. This patented reprogramming method allows for a single transfection step, inherent clearance of exogenous episomal DNA during cell division versus repeated passaging when using Sendai virus methods, and no introduction of viral DNA and subsequent viral protein expression.
This kit requires a media change every 48 hours during reprogramming, saving researchers hands-on time and media consumption.
Adherent Cells
Our proprietary expression platforms produce human recombinant growth factor proteins to produce best-in-class biologics with fully native post-translational modification
Suspension Cells
Our proprietary expression platforms produce human recombinant growth factor proteins to produce best-in-class biologics with fully native post-translational modification
A kit specifically designed to bring efficient cell reprogramming in-
house. Suitable for adherent or suspension-adapted primary cell
lines spanning somatic cells (e.g. Fibroblasts) to peripheral blood
mononuclear cells (PBMCs). Non-integrating episomal DNA is fully
cleared in 14 days and programmed cells exhibit footprint-free
characteristics and normal morphology.
Normal and disease model iPSCs that have been programmed using our proprietary method in the absence of MYC Lin28 proto-oncogenes. Cells display high pluriopotency markers and differentiation potential and adapted for suspension cell culture.
